Moderna's Phase 3 RSV vaccine trial follow-up data shows a 25% decline in efficacy, with its vaccine losing efficacy faster than those by GSK and Pfizer. Moderna shares fell 6% as a longer-term analysis revealed a quicker decline in efficacy compared to competitors.
ICYMI: The efficacy of Moderna’s investigational RSV vaccine appears to wane faster than GSK’s approved shot Arexvy $MRNA https://t.co/Rx4UEVWiEt
⚠️ MODERNA, BAYER-BACKED METAGENOMI STOCK DROPS 32% ON NASDAQ DEBUT (Reuters) Shares of Metagenomi Technologies, a genetic medicines company backed by Bayer Healthcare and Moderna, slumped 32% in their Nasdaq debut on Friday. The stock opened for trading at $10.25 compared…
Moderna’s RSV Vaccine May Lose Efficacy Faster Than GSK and Pfizer’s https://t.co/IcJnADGKUg
⚠️ MODERNA SHARES SLIDE AS LONGER-TERM DATA SHOWS QUICK FALL IN RSV VACCINE EFFICACY (Reuters) Moderna shares fell 6% on Friday after a longer-term analysis of a trial indicated a quicker fall in the efficacy of its experimental respiratory syncytial virus (RSV) vaccine. At…
Follow-up data from Moderna’s Phase 3 RSV vaccine trial reveals that its efficacy dwindles faster than vaccines made by GSK and Pfizer. The vaccine saw a 25% decline in efficacy. https://t.co/avsYR7PjYK